Alicja Puszkiel1,2, Mathilde Bauriaud-Mallet3, Roxane Bourgeois3, Lawrence Dierickx4, Frédéric Courbon4, Etienne Chatelut5,6. 1. Institut Claudius-Regaud, Institut Universitaire du Cancer Toulouse-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse, France. 2. CRCT, Cancer Research Center of Toulouse, Inserm U1037, Université Paul Sabatier, IUCT-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse, France. 3. Department of Radiopharmacy, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France. 4. Department of Medical Imaging, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France. 5. Institut Claudius-Regaud, Institut Universitaire du Cancer Toulouse-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse, France. chatelut.etienne@iuct-oncopole.fr. 6. CRCT, Cancer Research Center of Toulouse, Inserm U1037, Université Paul Sabatier, IUCT-Oncopole, 1 avenue Irène Joliot-Curie, 31059, Toulouse, France. chatelut.etienne@iuct-oncopole.fr.
Abstract
BACKGROUND AND OBJECTIVE: 177Lu-Dotatate is a radio-labeled analog of somatostatin used in the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. In order to prevent nephrotoxic effects of 177Lu-Dotatate a co-infusion of amino acids (AA) is administered, resulting in a decrease in tubular renal reabsorption of 177Lu-Dotatate. This study aimed to quantify the impact of AA co-infusion on the pharmacokinetics of 177Lu-Dotatate in cancer patients and to evaluate its relationship with toxicity during the first treatment cycle (C1). METHODS: 7.4 GBq of 177Lu-Dotatate was administered to 42 patients over a 30-min intravenous infusion. Infusion of AA started 2 h before and continued for 6 h after the infusion of 177Lu-Dotatate. Radioactivity-time data (n = 346) were analyzed using NONMEM® (version 7.2.0). RESULTS: 177Lu-Dotatate pharmacokinetics was best described by a three-compartment model with first-order elimination. AA co-infusion had a significant effect ('fixed effect') on 177Lu-Dotatate pharmacokinetics, with a mean value of 1.5-fold (95% confidence interval 1.03-1.97) increase in the elimination rate constant (k10) from 0.204 to 0.306 h-1, but this AA co-infusion effect was associated with a large inter-individual variability (IIV) of 104%. The individual k10 values increased during concomitant AA infusion by a factor ranging from 1.01 to 21.3 for 27 patients, whereas the opposite effect was observed in 15 patients (range 0.36-0.99) of whom seven had a k10 value lower than 0.85. This variability in AA effect contributed to the variability in 177Lu-Dotatate plasma exposure (area under the concentration-time curve from time zero to Day 15 for C1 [AUCDay15]) that correlated with lymphopenia observed at Day 15 (p = 0.004). CONCLUSIONS: A substantial effect of AA co-infusion on 177Lu-Dotatate pharmacokinetics was shown but was associated with high IIV, contributing to IIV in hematological toxicity.
BACKGROUND AND OBJECTIVE:177Lu-Dotatate is a radio-labeled analog of somatostatin used in the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. In order to prevent nephrotoxic effects of 177Lu-Dotatate a co-infusion of amino acids (AA) is administered, resulting in a decrease in tubular renal reabsorption of 177Lu-Dotatate. This study aimed to quantify the impact of AA co-infusion on the pharmacokinetics of 177Lu-Dotatate in cancerpatients and to evaluate its relationship with toxicity during the first treatment cycle (C1). METHODS: 7.4 GBq of 177Lu-Dotatate was administered to 42 patients over a 30-min intravenous infusion. Infusion of AA started 2 h before and continued for 6 h after the infusion of 177Lu-Dotatate. Radioactivity-time data (n = 346) were analyzed using NONMEM® (version 7.2.0). RESULTS:177Lu-Dotatate pharmacokinetics was best described by a three-compartment model with first-order elimination. AA co-infusion had a significant effect ('fixed effect') on 177Lu-Dotatate pharmacokinetics, with a mean value of 1.5-fold (95% confidence interval 1.03-1.97) increase in the elimination rate constant (k10) from 0.204 to 0.306 h-1, but this AA co-infusion effect was associated with a large inter-individual variability (IIV) of 104%. The individual k10 values increased during concomitant AA infusion by a factor ranging from 1.01 to 21.3 for 27 patients, whereas the opposite effect was observed in 15 patients (range 0.36-0.99) of whom seven had a k10 value lower than 0.85. This variability in AA effect contributed to the variability in 177Lu-Dotatate plasma exposure (area under the concentration-time curve from time zero to Day 15 for C1 [AUCDay15]) that correlated with lymphopenia observed at Day 15 (p = 0.004). CONCLUSIONS: A substantial effect of AA co-infusion on 177Lu-Dotatate pharmacokinetics was shown but was associated with high IIV, contributing to IIV in hematological toxicity.
Authors: Daniel I Chasman; Christian Fuchsberger; Cristian Pattaro; Alexander Teumer; Carsten A Böger; Karlhans Endlich; Matthias Olden; Ming-Huei Chen; Adrienne Tin; Daniel Taliun; Man Li; Xiaoyi Gao; Mathias Gorski; Qiong Yang; Claudia Hundertmark; Meredith C Foster; Conall M O'Seaghdha; Nicole Glazer; Aaron Isaacs; Ching-Ti Liu; Albert V Smith; Jeffrey R O'Connell; Maksim Struchalin; Toshiko Tanaka; Guo Li; Andrew D Johnson; Hinco J Gierman; Mary F Feitosa; Shih-Jen Hwang; Elizabeth J Atkinson; Kurt Lohman; Marilyn C Cornelis; Asa Johansson; Anke Tönjes; Abbas Dehghan; Jean-Charles Lambert; Elizabeth G Holliday; Rossella Sorice; Zoltan Kutalik; Terho Lehtimäki; Tõnu Esko; Harshal Deshmukh; Sheila Ulivi; Audrey Y Chu; Federico Murgia; Stella Trompet; Medea Imboden; Stefan Coassin; Giorgio Pistis; Tamara B Harris; Lenore J Launer; Thor Aspelund; Gudny Eiriksdottir; Braxton D Mitchell; Eric Boerwinkle; Helena Schmidt; Margherita Cavalieri; Madhumathi Rao; Frank Hu; Ayse Demirkan; Ben A Oostra; Mariza de Andrade; Stephen T Turner; Jingzhong Ding; Jeanette S Andrews; Barry I Freedman; Franco Giulianini; Wolfgang Koenig; Thomas Illig; Christa Meisinger; Christian Gieger; Lina Zgaga; Tatijana Zemunik; Mladen Boban; Cosetta Minelli; Heather E Wheeler; Wilmar Igl; Ghazal Zaboli; Sarah H Wild; Alan F Wright; Harry Campbell; David Ellinghaus; Ute Nöthlings; Gunnar Jacobs; Reiner Biffar; Florian Ernst; Georg Homuth; Heyo K Kroemer; Matthias Nauck; Sylvia Stracke; Uwe Völker; Henry Völzke; Peter Kovacs; Michael Stumvoll; Reedik Mägi; Albert Hofman; Andre G Uitterlinden; Fernando Rivadeneira; Yurii S Aulchenko; Ozren Polasek; Nick Hastie; Veronique Vitart; Catherine Helmer; Jie Jin Wang; Bénédicte Stengel; Daniela Ruggiero; Sven Bergmann; Mika Kähönen; Jorma Viikari; Tiit Nikopensius; Michael Province; Shamika Ketkar; Helen Colhoun; Alex Doney; Antonietta Robino; Bernhard K Krämer; Laura Portas; Ian Ford; Brendan M Buckley; Martin Adam; Gian-Andri Thun; Bernhard Paulweber; Margot Haun; Cinzia Sala; Paul Mitchell; Marina Ciullo; Stuart K Kim; Peter Vollenweider; Olli Raitakari; Andres Metspalu; Colin Palmer; Paolo Gasparini; Mario Pirastu; J Wouter Jukema; Nicole M Probst-Hensch; Florian Kronenberg; Daniela Toniolo; Vilmundur Gudnason; Alan R Shuldiner; Josef Coresh; Reinhold Schmidt; Luigi Ferrucci; David S Siscovick; Cornelia M van Duijn; Ingrid B Borecki; Sharon L R Kardia; Yongmei Liu; Gary C Curhan; Igor Rudan; Ulf Gyllensten; James F Wilson; Andre Franke; Peter P Pramstaller; Rainer Rettig; Inga Prokopenko; Jacqueline Witteman; Caroline Hayward; Paul M Ridker; Afshin Parsa; Murielle Bochud; Iris M Heid; W H Linda Kao; Caroline S Fox; Anna Köttgen Journal: Hum Mol Genet Date: 2012-09-08 Impact factor: 6.150
Authors: Edgar J Rolleman; Eric P Krenning; Bert F Bernard; Monique de Visser; Magda Bijster; Theo J Visser; Marcel Vermeij; Jan Lindemans; Marion de Jong Journal: Eur J Nucl Med Mol Imaging Date: 2006-09-22 Impact factor: 9.236
Authors: Marleen Melis; Eric P Krenning; Bert F Bernard; Raffaella Barone; Theo J Visser; Marion de Jong Journal: Eur J Nucl Med Mol Imaging Date: 2005-05-24 Impact factor: 9.236
Authors: Dik J Kwekkeboom; Wouter W de Herder; Boen L Kam; Casper H van Eijck; Martijn van Essen; Peter P Kooij; Richard A Feelders; Maarten O van Aken; Eric P Krenning Journal: J Clin Oncol Date: 2008-05-01 Impact factor: 44.544
Authors: Tsin W Yeo; Indri Rooslamiati; Retno Gitawati; Emiliana Tjitra; Daniel A Lampah; Enny Kenangalem; Yvette R McNeil; Richard N Price; Nicholas M Anstey; Stephen B Duffull Journal: Antimicrob Agents Chemother Date: 2008-10-06 Impact factor: 5.191
Authors: Sibel Kantarci; Lihadh Al-Gazali; R Sean Hill; Dian Donnai; Graeme C M Black; Eric Bieth; Nicolas Chassaing; Didier Lacombe; Koen Devriendt; Ahmad Teebi; Maria Loscertales; Caroline Robson; Tianming Liu; David T MacLaughlin; Kristin M Noonan; Meaghan K Russell; Christopher A Walsh; Patricia K Donahoe; Barbara R Pober Journal: Nat Genet Date: 2007-07-15 Impact factor: 38.330
Authors: P J Hammond; A F Wade; M E Gwilliam; A M Peters; M J Myers; S G Gilbey; S R Bloom; J Calam Journal: Br J Cancer Date: 1993-06 Impact factor: 7.640
Authors: E A Aalbersberg; B J de Wit-van der Veen; M W J Versleijen; L J Saveur; G D Valk; M E T Tesselaar; M P M Stokkel Journal: Eur J Nucl Med Mol Imaging Date: 2018-08-10 Impact factor: 9.236